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 The use of immune checkpoint inhibitors and BRAF and MEK protein inhibitors in patients with advanced melanoma re-
sulted in the overall survival median exceeding 2 years. For ipilimumab and anti-PD-1 antibodies, the percentage of 5-year 
survival is about 20% and 35%, respectively. Better results are obtained by patients treated in the first-line treatment. The 
most effective option seems to be the combined use of anti-CTLA-4 antibody with anti-PD antibody – in this case the 
percentage of 4-year overall survival was 53%. The 5-year overall survival rate of patients treated with BRAF/MEK inhibitors 
is 34%. Patients with a early stage of disease and normal lactate dehydrogenase concentration before systemic treatment 
are more likely to benefit from treatment.
NOWOTWORY J Oncol 2019; 69, 3–4: 117–124
Key words: ipilimumab, pembrolizumab, nivolumab, dabrafenib, trametinib, long-term survival, melanoma
Introduction
In 2011, two new drugs were approved, which changed the 
prognosis of patients with advanced melanoma – ipilimumab 
[1] and vemurafenib [2]. Both drugs became representatives
of new groups of drugs – immune checkpoints inhibitors and 
BRAF protein inhibitors. Less than a decade ago, the median
overall survival rate for patients with advanced melanoma
was 6–8 months, and the chance of 5- year survival ranged
from 5% to 10% [3]. Molecularly targeted drugs and immu-
notherapy currently allow to reach the median total survival
of more than 2 years. 
Immunotherapy
Ipilimumab
In 2015, data on 3-year survival in patients treated with ipili-
mumab in phase II and phase III studies were published. 1861 
patients were included in the analysis; 1257 patients received 
ipilimumab in the second or subsequent lines. The majority 
of patients [n = 965] received 3 mg/kg of body weight; 706 
patients received 10 mg/kg of body weight; the remaining 190 
patients received ipilimumab in a different dose. All patients 
received at least 4 doses of the drug at three-week intervals. 
In some studies, patients may have received maintenance 
treatment or may have been re-treated inductively after the 
progression of the disease. Overall survival (OS) was 11.4 mon-
ths (95% confidence interval – CI): 10.7–12.1 months) with 
a 3-year OS percentage estimated at  22% (95% CI: 20%–24%). 
The median of the follow-up period was 11 months. Ten per-
cent of patients were followed-up for at least 50 months. 
The maximum follow-up time was impressive and it was 119 
months. The overall survival curve flattened at about 3 years 
after the start of treatment (fig. 1).
Longer overall survival was observed in patients receiving 
ipilimumab in the first line of treatment (median 13.5 months) 
compared to patients previously receiving systemic treatment 
(median 10.7 months). The 3-year survival rate for these groups 
was 26% and 20% respectively. 
No significant differences in overall survival were observed 
in patients depending on ipilimumab doses. 
To this group 2985 patients from the program of exten-
ded access to ipilimumab (EAP) (4846 patients in total) were 
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added. In this program, ipilimumab was also used to treat 
patients who would not meet the criteria for inclusion in the 
majority of clinical trials: patients with efficiency level 2 on the 
ECOG scale, patients with metastases in the brain, patients 
with melanoma of mucous membranes and eyeballs. The OS 
median for the entire group was 9.5 months with a 3-year total 
survival rate of 21%. 
Among 88 patients who survived at least 4 years and were 
treated in studies CA 184-007, CA 184-008 and CA 184-022, 35 
(40%) obtained an objective response, 29 (33%) disease sta-
bilization and in 22 (25%) there was a progress in the disease. 
Therefore, the lack of an objective answer did not prejudge 
the short-term survival. 
This data confirms observations from other studies inc-
luded in this analysis, as well as coincides with observations 
from clinical practice [4].
In 2015, an analysis of the long-term survival o patients who 
were treated in the third phase of the study CA 184-024 (dacar-
bazine + ipilimumab 10 mg/kg of body weight) vs. dacarbazine 
+ placebo) was published. The study showed significantly longer 
OS in the group treated with ipilimumab and dacarbazine than 
in the group treated with dacarbazine in monotherapy: 11.2 
months vs. 9.1 months (hazard ratio [HR] 0.72, p < 0.001). 
502 patients were treated with 250 ipilimumab with da-
carbazine and 252 with dacarbazine. After 5 years, 40 patients 
receiving ipilimumab and 20 patients receiving monotherapy 
still lived (fig. 2). 
The percentage of 5-year overall survival for combined 
therapy was 18.2%, and for dacarbazine 8.8%. Responses to 
treatment were assessed using modified WHO criteria. In the 
group of patients receiving ipilimumab with dacarbazine, 
complete response (CR) was observed in 7.5%, while partial 
response (PR) was observed in 42.5% of patients. In the group 
of patients receiving dacarbazine in monotherapy, no com-
plete responses were observed, and partial responses were 
observed in 35% of treated patients. 
Figure 2. Long-term survival in patients treated with ipilimumab compared with dacarbazine [5]
Figure 1. Long-term survival in patients treated with ipilimumab depending on the treatment line [4]
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Longer overall survival was observed in patients with 
objective response to treatment. In the group treated with 
ipilimumab with dacarbazine, median OS was not achieved 
in patients with objective response to treatment. In the group 
of patients where no response was achieved, the median OS 
was 14.3 months (HR 0.28; 95% CI: 0.16–0.47). Similarly, better 
survival rates were observed in patients with objective respon-
se to dacarbazine in monotherapy compared to patients with 
no response to treatment. The median OS was 20.2 and 12.3 
months respectively (HR 0.51; 95% CI: 0.32–0.84) [5].
Two studies on patients treated with ipilimumab in phase 
I and II studies are interesting in terms of long-term survival. 
The first one describes 177 patients [6], who were treated in 
3 studies, for which recruitment was conducted in the years 
2003–2005. Ipilimumab was administered in combination with 
gp100 peptide, high-dose interleukin 2 or alone. The drug was 
administered in different patterns. The analysis presents data 
of 15 patients with complete response (CR). At the time of 
publication, 14 patients were alive. The time to obtain CR was 
very different – from 3 to even 70 months. The longest duration 
of CR was 99 months. In 1 patient the disease progressed after 
42 months of complete response. 
The data of 18 patients who were alive at the time of the 
analysis and who did not obtain CR were also presented. For 
3 of them, a partial response has been maintained for 56, 66 
and 71 months. In 6 patients metastasectomy or other local 
treatment, including radiation therapy or percutaneous radio-
-frequency ablation (RFA) was chosen. The remaining patients 
underwent other systemic treatment – chemotherapy, targe-
ted therapy, biological treatment, immunotherapy. 
The percentage of 5-year overall survival; for the three 
analysed studies was 13%, 25% and 23% respectively. 
The second analysis concerns 733 patients treated with 
ipilimumab in 6 phase II studies. They received ipilimumab at 
a dose of 0.3, 3 or 10 mg/kg of body weight. In the group of 
patients who were previously treated, the percentage of 5-year 
overall survival was 12.3%, 12.3–16.5% and 15.5–28.4%, respec-
tively. The percentage of 5-year overall survival in the group of 
patients untreated earlier was 26.8% for those receiving 3 mg/
kg of body weight and 21.4–49.5% for those receiving 10 mg/
kg of body weight [7].
In 2017, a retrospective analysis of 1034 patients treated 
under the European extended access programme (EURO-
-VOYAGE) was published. 
The OS median was 6.8 months, with 3- and 4-year survival 
rates of 10.9% and 8%, respectively. The patient survival in this 
group was much shorter than in other studies. The reason for 
such results was the wider criteria for inclusion in the extended 
access program than in clinical trials [8].
According to the available data, patients in the first-line 
treatment received a greater benefit from ipilimumab treat-
ment. Since 2014, when the results of anti-PD-1 antibodies 
tests were published, it has been known that they are a better 
choice for patients than ipilimumab. Data on the efficacy of 
ipilimumab after progression during anti-PD-1 treatment are 
limited, however, this drug remains an option in the second 
line in patients without BRAF mutations. 
Anti-PD-1 antibodies
In the first line of treatment of patients with advanced mela-
noma, anti-PD-1 antibodies, i.e. pembrolizumab [9] and nivo-
lumab [10], are currently the preferred choice. 
Pembrolizumab
In 2019, the analysis of long-term survival of patients treated 
in the phase Ib of the open-label study KEYNOTE -001 was 
published. The study included 655 patients with advanced 
melanoma, including 8 patients with diagnosis of advanced 
untreated melanoma of the eyeball. Most patients (n = 496) 
had previously received systemic treatment (205 received 
one line of treatment, 178 received two lines of treatment, 
113 received 3 or more lines of treatment). The percentage 
of 5-year PFS was 21% for the whole population; and 29% for 
patients treated in line 1. The median of the follow-up period 
was 55 months. The longest response lasts for 66 months. The 
percentage of 5-year survival in the whole group was 34%, and 
41% in the subgroup treated in the first line. The OS median 
for the whole population was 23.8 months (95% CI: 20.2–30.4), 
whereas for patients treated in the first line it was 38.6 months 
(95% CI: 27.2 – not reached) (fig. 3).
Complete response to treatment was obtained in 16% of 
patients, partial response in 25% of patients, and stabilization 
of the disease in 24% of patients. At the time of analysis of the 
response data, 93 patients (89%) still had a complete response 
and 102 (63%) had a partial response. The protocol assumed 
that pembrolizumab could be discontinued in patients after 
a good response to treatment. Among the patients who ended 
CR treatment in this way, 67 patients were observed, and 5 pa-
tients were treated with PR. Only 7 of these patients developed 
progression after discontinuation of pembrolizumab (6 CR, 
1 PR); 90% of the responses were still present. Of these 7 pa-
tients, 4 received pembrolizumab again. One patient obtained 
CR again, one SD; 2 patients experienced further progression 
of the disease [11] (fig. 4).
KEYNOTE-006 was the second study to analyse the long-
-term survival in patients with advanced melanoma. In this 
phase III study patients were randomized to 3 arms: 
• pembrolizumab 10 mg/kg of body weight every 2 weeks,
•  pembrolizumab 10 mg/kg of body weight every 3 weeks,
• ipilimumab 3 mg/kg of body weight (4 applications). 
Patients could receive only one line of treatment befo-
rehand. Pembrolizumab was administered for a maximum 
of 2 years. 
The OS median for both arms of pembrolizumab was 
32.7 months (95% CI: 24.5–41.6), for ipilimumab was 15.9 mon-
ths (95% CI: 13.3–22.0), (HR 0.73, 95% CI: 0.61–0.88, p = 0.00049]. 
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The percentage of 5-year overall survival was 38.7% for both 
groups of pembrolizumab and 31% for ipilimumab group. 
Patients who received pembrolizumab or ipilimumab in the 
first line had better results – median OS in these groups was 
38.7 months (95% CI: 27.3–50.7) and 17.1 months (95% CI: 
13.8–26.2). 
Pembrolizumab used in the second line of treatment allo-
wed to reach the median OS at the level of 23.5 months (95% 
CI: 16.8–34.2). The OS median for ipilimumab used in the 2nd 
line was 13.6 months (95% CI: 10.7–22.0).
For 2 years 103 patients (19%) received pembrolizumab; 
21 of them obtained CR, 69 – PR and 13 – SD as the best 
response. After the median observation period at the end 
of pembrolizumab 34.2 months, the studied percentage of 
2-year PFS was 78.4% (95% CI: 68.3–85.6). The percentage of 
2-year and 3-year OS was 95.9% (95% CI: 89.4–98.4) and 93.8% 
(95% CI: 86.7–97.2). 
In the group of patients who ended treatment with pem-
brolizumab after 2 years, the median time to progression of 
the disease was 33.3 months after the end of pembrolizumab 
administration. Thirteen patients in whom the disease pro-
gressed after the end of treatment received pembrolizumab 
again. In this group the percentage of CR was 23%, PR – 31% 
and SD – 15%. In one patient the disease progressed further 
and in 2 patients the response to treatment was not assessed 
yet [12, 13].
Nivolumab
One of the first studies of long-term survival was the analysis of 
patients participating in the first phase of the study CA209–003. 
The percentage of 5-year survival in the group of patients 
treated for advanced melanoma was 34% – a similar result 
was obtained in patients treated with pembrolizumab [14].
Figure 3. Long-term survival in the whole population (A) and in the previously untreated group (B) [11]
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Recently, the long-term results of Checkmate-067 have 
been published. It was a phase III study in which patients were 
randomly assigned to one of the three arms: 
• nivolumab, 
• ipilimumab or 
• nivolumab and ipilimumab. 
Nivolumab in monotherapy or in combination with ipi-
limumab significantly improved PFS and OS compared to 
ipilimumab in monotherapy. After at least 48 months of obse-
rvation the median OS was not achieved for the group treated 
with ipilimumab and nivolumab (95% CI: 38.2 – not reached) 
In the remaining arms, the median OS for nivolumab and ipi-
limumab was 36.9 (95% CI: 28.3 – not achieved) months and 
19.9 (95% CI: 16.9−24.6) months.
The percentage of 4-year overall survival was 53% for 
combined therapy, 46% for nivolumab and 30% for ipilimumab. 
Both groups treated with nivolumab achieved significantly lon-
ger overall survival compared to those treated with ipilimumab. 
No statistically significant differences in overall survival betwe-
en nivolumab and ipilimumab and nivolumab were found (HR 
0.84, 95% CI: 0.67–1.05). An interesting observation from this 
analysis was the comparison of total survival depending on 
the initial concentration of lactate dehydrogenase (LDH). In the 
group of patients in whom LDH concentration exceeded the 
upper limit of norm by more than 2 times, the percentage of 
4-year overall survival was as high as in the group of patients 
in whom LDH concentration exceeded the upper limit of 
norm: 28% in patients receiving nivolumab with ipilimumab, 
14% in patients receiving nivolumab and only 7% in patients 
receiving ipilimumab [15].
Anti-PD-1 antibodies
For anti-PD-1 antibodies the overall survival curves after 3 
years reach a plateau at about 40%. The problem with treating 
patients with immunotherapy with anti-PD-1 antibodies in 
monotherapy or in combination with anti-CTLA-4 antibodies 
is to determine the optimal duration of treatment. PET-TK exa-
mination, in some cases in combination with biopsy, may be a 
helpful tool in deciding to discontinue immunotherapy [16, 17]. 
Another problem is the relapse of the disease after an ear-
lier discontinuation of immunological treatment after a long-
-term response. Available data confirm the need for this type 
of treatment again due to the possibility of a further response 
[18]. In Poland, however, current records of drug programs with 
anti-PD-1 antibodies do not allow for the possibility of re-tre-
atment with anti-PD-1 in patients with advanced melanoma.
Achieving a long-term response to treatment is desirable 
for any patient who is struggling with a deadly disease. One 
may feel that the patients who get these results are constantly 
satisfied, but they have to struggle with a constant fear of 
relapse. There are currently no data on potential long-term 
adverse effects on cognitive capacity or emotional sphere in 
this group of patients [19].
Treatment with BRAF or MEK inhibitors
One of the analyses concerning the long-term survival of 
patients with advanced melanoma with BRAF V600 mutation 
treated with BRAF inhibitors is a study concerning the second 
phase (randomized) of BRF113220 study [20]. Part C of the 
study included 162 patients who were assigned to one of three 
groups (54 patients in each group) treated with: 
• dabrafenib as monotherapy (D), 
• dabrafenib 150 mg/day + trametinib 1 mg/day (D + T 
150/1) or 
• dabrafenib 150 mg/day + trametinib 2 mg/day (D + T 
150/2). 
The percentage of 4-year and 5-year PFS was 13% (95% 
CI: 5–25) in the arm D + T 150/2, 9% and 3% (95% CI: 0–11%) 
in the arm with monotherapy. The percentage of 4-year and 
5-year OS was 30% (95% CI: 18–43%) and 28% (95% CI: 17–41%) 
respectively for D + T 150/2 and 23% (95% CI: 13-35%) and 21% 
(95% CI: 11–33%) for D with monotherapy. The percentage 
of 5-year overall survival was similar in patients treated with 
D + T 150/1 and D + T 150/2 (33% vs. 28%). 
Further anticancer treatment resulted in a higher num-
ber of patients on the D arm in monotherapy than in the 
D + T 150/2 arm. The most frequent subsequent treatment 
regimens were immunotherapy (37% vs. 43% for D + T 150/2 
and D respectively as monotherapy) and targeted treatment 
(24% vs. 87%). 
A complete response to treatment  according to Response 
Evaluation Criteria in Solid Tumors (RECIST) was reported in 9 
(17%) patients in the D + T 150/2 arm and 2 (4%) patients in 
the monotherapy arm. In the subgroup of patients with CR in 
the D + T 150/2 arm, the percentage of 4- and 5-year OS was 
56% and 44%, respectively, at the median OS 53.4 months. 
In the subgroup of patients with normal LDH levels, the 
percentage of 4-year and 5-year survival in the D + T 150/2 
arm was 48% (95% CI: 30–64%) and 45% (95% CI: 27–61%). In 
the monotherapy arm, the values were 31% (95% CI: 15–50%) 
and 26% (95% CI: 11–45%). Patients with normal LDH levels, in 
whom the cancer developed in three (or less) locations, bene-
fited most from treatment [21, 22]. The percentage of 4-year 
and 5-year OS was 57% (95% CI: 32–76%) and 51% (95% CI: 
27–71%) respectively for D + T 150/2 and 42% (95% CI: 15–67%) 
and 31% (95% CI: 8–58%) for the arm treated with dabrafenib.
Five-year survivals were analysed in a group of 563 pa-
tients who received dabrafenib and trametinib in two phase 
III studies: COMBI-d (211 patients) and COMBI-v (352 patients) 
[23]. The percentage of 4- and 5-year progression-free survival 
was 21% and 19%, respectively. In patients with normal LDH 
levels at initiation of treatment, the 5-year PFS percentage was 
25%, compared to 8% in patients with LDH levels above the 
upper limit of normal. 
Previous analysis, including the data of patients treated in 
the above two studies and one phase II study (617 patients in 
total), allowed us to identify a subgroup reaching a significan-
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tly longer time to progression of the disease. There were 216 
patients (38%) who had normal LDH levels at the beginning 
of treatment and at locations of the disease [21]. This group 
reached a 5-year PFS of 31%. The OS median for the whole po-
pulation was 25.9 months (95% CI: 22.6–31.5). The percentage 
of 4- and 5-year overall survival was 37% and 34%, respectively. 
Patients with normal LDH concentration had better prognosis 
than patients with elevated LDH concentration. The percenta-
ge of 5-year OS was 43% and 16% respectively. In the subgroup 
of patients with normal LDH concentration and limited to 
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3 occupied areas, the percentage of 5-year OS was estimated 
at 55 % (95% CI: 48–61) (fig. 5).
Of the 161 patients who lived at the time of analysis, 69 
(43%) received dabrafenib, trametinib or both. Further anti-
cancer therapy was administered to 72 patients (45%). Most 
often it was immunotherapy – 56 patients (78%), 42 (67%) 
received anti-PD-1 and 30 (42%) anti-CTLA-4 antibodies. In 
the remaining 89 patients (55%) no anticancer treatment of 
the next line was administered. 
In the whole analysed population, further treatment lines 
were administered in 299 out of 563 patients (53%). Immuno-
therapy was the most frequent choice – 196 of 299 patients 
(66%) received it, including 151 (51%) treated with anti-PD-1 
and 102 (34%) with anti-CTLA-4 antibodies. 
Objective responses were recorded in 68% of patients, inc-
luding total responses at 19% (109 patients). The percentage of 
5-year OS in the group of patients with CR was 71%; in patients 
with PR this percentage was 32%, and in patients with disease 
stabilization – 16% (fig. 1). 6). The median of the CR period was 
36.7 months. Table I shows the factors influencing survival free 
from disease progression and overall survival.
Summary
The use of anti-PD-1 antibodies and BRAF/MEK inhibitors in 
the group of patients with positive BRAF mutation allows to 
achieve long-term overall survival in about 1/3 of patients with 
advanced melanoma. Long-term responses to treatment are 
most often observed in patients with low disease severity and 
normal lactate dehydrogenase concentration before systemic 
treatment. In patients with melanoma with more aggressive 
course, a combination of anti-CTLA-4 and anti-PD-1 antibo-
dies seems to be more effective in immunotherapy. However, 
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124
this group of patients still requires new therapeutic options. 
Several ongoing clinical trials are aimed at answering the 
question about the correct sequence of treatment and the 
appropriateness of using immunotherapy in combination 
with targeted treatment. 
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Table I. Analysis of factors influencing survival free from disease progression and overall survival
Variable Result tested (n) PFS OS
HR (CI 95%) p HR p
Sex Women (238) vs. men (313) 0.74 (0.61–0.90) 0.003 0.68 (0.55–0.84) <0.001
BRAF mutation V600E (482) vs. V600E or V600K plus V600K (69) 0.65 (0.49–0.87) 0.004 0.77 (0.55–1.06) 0.11
General condition ECOG 0 (398) vs. ECOG ≥1 (153) 0.68 (0.55–0.85) <0.001 0.49 (0.39-0.62) <0.001
LDH concentration Normal (359) vs. elevated (192) 0.50 (0.40–0.64) <0.001 0.47 (0.37–0.61) <0.001
Number of locations with disease <3 locations (282) vs. ≥3 locations (269) 0.72 (0.58–0.91) 0.005 0.58 (0.46–0.74) <0.001
